Action of Thalidomide Drug on Female and Male E/Beta Thalassemia Patients
Thalassemia Curing, Thalidomide Drug. Thalidomide. Hemoglobin. MCV. MCH. MCHC. HCT level comparison
The idea of thalidomide drugs being effective in treating beta-thalassemia patients and in this case, beta-thalassemia was successfully treated. Thalidomide, sold under the brand names Contergan and Thalomide, is a medication used to treat cancers (including multiple myeloma) and graft-versus-host disease, as well as skin conditions including complications of leprosy. HIV-associated conditions have been treated with it, but such treatment has been associated with increased virus levels. It is taken orally. In addition to improving hemoglobin count, thalidomide also improved other important factors in patients. The use of this drug as per the data we got by implementing them in thalassemia patients has been recommended with proper dosage. Females generally respond better to this drug than males. Thalidomide, in its entirety, might not be a game-changer, but a temporary treatment for thalassemia that keeps patients on track with hemoglobin counts.
"Action of Thalidomide Drug on Female and Male E/Beta Thalassemia Patients", IJSDR - International Journal of Scientific Development and Research (www.IJSDR.org), ISSN:2455-2631, Vol.6, Issue 7, page no.67 - 70, July-2021, Available :https://ijsdr.org/papers/IJSDR2403009.pdf
Volume 6
Issue 7,
July-2021
Pages : 67 - 70
Paper Reg. ID: IJSDR_210271
Published Paper Id: IJSDR2403009
Downloads: 000347354
Research Area: Biological Science
Country: Nadia, West Bengal, India
ISSN: 2455-2631 | IMPACT FACTOR: 9.15 Calculated By Google Scholar | ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 9.15 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Publisher: IJSDR(IJ Publication) Janvi Wave
